Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab

Breast

Volumn 21, Issue 3, 2012, Pages 309-313

  Dellapasqua, Silvia ^a   Bagnardi, Vincenzo ^b   Bertolini, Francesco ^a   Sandri, Maria Teresa ^a   Pastrello, Davide ^a   Cancello, Giuseppe ^a   Montagna, Emilia ^a   Balduzzi, Alessandra ^a   Mancuso, Patrizia ^a   Luini, Alberto ^a   Goldhirsch, Aron ^a,c   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Angiogenesis; Bevacizumab; Macrocytosis; Metastatic breast cancer; Metronomic chemotherapy; Predictive factor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; ERLOTINIB; HEMOGLOBIN; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; DRUG RESPONSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; METASTASIS; METRONOMIC DRUG ADMINISTRATION; MORNING DOSAGE; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 84862570397     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.01.015     Document Type: Article

References (29)

1. Buzdar A.U., Michaud B., Hortobagyi G.N. What is the optimal duration of chemotherapy in advanced breast cancer?. Abstr 10th Int Congr on anti-cancer treatment 2000, 45-47.
2. Coates A., Stat V.G.M., Bishop J.F., Jeal P.N., Woods R.L., Snyder R., et al. Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 1987, 317:1490-1495.
3. Gregory R.K., Powles T.J., Chang J.C., Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 1997, 33:2194-2197.
4. Harris A.L., Cantwell B.M.J., Carmichael J., Wilson R., Farndon J., Dawes P., et al. Comparison of short-term and continuous chemotherapy (mitoxantrone) for advanced breast cancer. Lancet 1990, 335:186-190.
5. Muss H.B., Case L.D., Richards F., White D.R., Cooper M.R., Cruz J.M., et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 1991, 325:1342-1348.
6. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000 Sep 14, 407(6801):249-257.
7. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005 Feb 10, 23(5):1011-1027.
8. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002 Oct, 2(10):727-739.
9. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004 Jun, 4(6):423-436.
10. Bocci G., Nicolaou K.C., Kerbel R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002 Dec 1, 62(23):6938-6943.
11. Wenzel C., Mader R.M., Steger G.G., Pluschnig U., Kornek G.V., Scheithauer W., et al. Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies. Anti-Cancer Drugs 2003, 14:119-123.
12. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26(30):4899-4905.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
14. http://ctep.cancer.gov/forms/CTCAEv3.pdf.
15. Thiébaut R., Jacqmin-Gadda H., Chêne G., Leport C., Commenges D. Bivariate linear mixed models using SAS proc MIXED. Comput Metods Programs Biomed 2002 Nov, 69(3):249-256.
16. Verbeke G., Molenberghs G. Linear mixed models for longitudinal data 2000, Springer, New York.
17. Karvellas C.J., Sawyer M., Hamilton M., Mackey J.R. Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. Am J Clin Oncol 2004, 27:364-368.
18. Sun J.F., Wu R.R., Norris C., Noone A.M., Amankwa-Sakyi M., Slack R., et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. Gastrointest Cancer Res 2009, 1:134-140.
19. Takebayashi Y., Akiyama S., Akiba S., Yamada K., Miyadera K., Sumizawa T., et al. Clinicopathologic and prognostic significance of an angiogenetic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996, 88:1110-1117.
20. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998, 34:1274-1281.
21. Ishikawa T., Fukase Y., Yamamoto T., Sekiguchi F., Ishitsuka H. Antitumor activities of a novel fluoropyrimidine, N 4-pentoxycarbonyl-5-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull 1998, 21:713-717.
22. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998, 58:685-690.
23. Van Triest B., Pinedo H.M., Blaauwgeers L.G., van Diest P.J., Schoenmakers P.S., Voorn D.A., et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000, 6:1063-1072.
24. Peters G.J., Jansen G. Resistance to antimetabolites. Principles of antineoplastic drug development and pharmacology 1996, 543-585. Marcel Dekker, New York. R.L. Schilsky, G.A. Milano, M.J. Ratain (Eds.).
25. Hoffbrand A.V., Waters A.H. Observations on the biochemical basis of megaloblastic anaemia. Br J Haematol 1972, 23:109-118.
26. Rini B.I., Choueiri T.K., Elson P., Khasawneh M.K., Cotta C., Unnithan J., et al. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008, 113:1309-1314.
27. Aliberti S., Grignani G., Allione P., Vormola R., Bucci A., Porrino G., et al. Erythrocyte macrocytosis is a rather common, apparently uneventful yet unexplained finding in GIST imatinib chronic therapy. J Clin Oncol 2005, 23(16S):9045. ASCO Annual Meeting Proceedings.
28. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
29. Allegra C. Thymidylate synthase levels: prognostic, predictive, or both?. J Clin Oncol 2002, 20:1711-1713.